Other Information
−Removed: During the three months ended September 30, 2024, none of our directors or officers (as defined in Rule 16a-1(f) of the Exchange Act) adopted or terminated any contract, instruction, or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act or any non-Rule 10b5-1 trading arrangement (as defined in the SEC’s rules).
−Removed: Number Incorporated by Reference Filed Herewith
+Added: During the three months ended March 31, 2025, one of our directors or officers (as defined in Rule 16a-1(f) of the Exchange Act) adopted or terminated a contract, instruction, or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act or any non-Rule 10b5-1 trading arrangement (as defined in the SEC’s rules).
+Added: The material terms of the Rule 10b5-1 trading arrangement are described below:
+Added: Name and Title Action Taken Type of Trading Arrangement Nature of Trading Arrangement Duration of Trading Arrangement Number of Securities
+Added: Jon Congleton , President, Chief Executive Officer, and Director
+Added: Adoption January 28, 2025
+Added: Trading plan intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c) Sale of the Company’s common stock pursuant to the terms of the plan January 1, 2026 to December 31, 2026
+Added: (1) The executive’s Rule 10b5-1 trading arrangement provides for the sale of up to 575,270 shares of common stock subject to a restricted stock award granted to Mr.
+Added: Congleton that vests ratably over time.
+Added: Incorporated by Reference Filed Herewith
Exhibit Description Form Date Number
3 unchanged sentences
8-K 2/14/23 3.2
+Added: Mineralys Therapeutics, Inc.
+Added: 2025 Employment Inducement Incentive Award Plan and form of stock option agreement and form of restricted stock unit agreement thereunder
31.1 Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
15 unchanged sentences
MINERALYS THERAPEUTICS, INC.
−Removed: November 12, 2024 By:
+Added: May 12, 2025 By:
/s/ Jon Congleton
Jon Congleton
−Removed: Chief Executive Officer
+Added: President and Chief Executive Officer
(Principal Executive Officer)
−Removed: November 12, 2024 By:
+Added: May 12, 2025 By:
/s/ Adam Levy
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.